25 research outputs found

    Is the Revitalisation of Smallholder Irrigation Schemes (RESIS) programme in South Africa a viable option for smallholder irrigation development?

    Get PDF
    Smallholder irrigation in South Africa comprises only 3% of the irrigated area. Despite this relatively small area share, Limpopo Province is using the development of smallholder irrigation as a way of developing rural areas and correcting historical imbalances. Unlike the smallholder irrigation developed in most African countries, which focuses mainly on food security through subsistence production, Limpopo Province aims to develop commercial smallholder irrigation. Plots in this model are not fragmented. Initially the farmers are paired with a strategic partner knowledgeable about both the operation of irrigation and the crops grown. After 3 years the strategic partner transfers all ownership to farmers. We use gross margin analysis from one production cycle to assess the financial viability of this model. We conclude that there is potential for the model to be financially viable if farmers can get access to cash flow support in the form of credit which they can pay off at the end of a production cycle. This could be an innovative way of smallholder agricultural water management and of transforming poor subsistence farmers to commercial producers and thereby correcting historical imbalances.Keywords: smallhoder irrigation, financial viability, gross margin, South Afric

    Gene and cell therapy in South Africa: Current status and future prospects

    Get PDF
    South Africa has a high disease burden resulting from communicable and non-communicable diseases. Current therapeutic interventions rarely result in a cure and the associated lifelong treatment places a considerable strain on an overburdened health sector. Gene and cell therapies present novel alternatives to disease management, offering the promise of a single treatment and a lifelong cure. Although challenges remain, investment in the field has started to bear fruit, with a number of gene and cell therapeutics reaching the market in the past decade. To take full advantage of these developments, it is important that a proactive approach to nurturing appropriate human and material resources is adopted in the country

    Protecting participants in health research: The South African Material Transfer Agreement

    Get PDF
    The need to transfer human biological materials (HBMs) across national boundaries has become increasingly important in view of increased biobank and commercial activities globally. In light of South Africa (SA)’s history of colonisation and racial discrimination, coupled with well-known instances of exploitation of research participants in the developing world, it is critical that the management of HBMs from and to other jurisdictions is explored and regulated. Material transfer agreements (MTAs) represent an important point of departure in such a process. This article explores the need for a uniform MTA in SA and discusses some aspects of the recently gazetted national MTA, which provides a framework that can serve as a safeguard for cross-border transfer of HBMs in the absence of the National Health Act’s chapter 8 regulations in this regard

    Protecting participants in health research: The South African Material Transfer Agreement

    Get PDF
    The need to transfer human biological materials (HBMs) across national boundaries has become increasingly important in view of increased biobank and commercial activities globally. In light of South Africa (SA)’s history of colonisation and racial discrimination, coupled with well-known instances of exploitation of research participants in the developing world, it is critical that the management of HBMs from and to other jurisdictions is explored and regulated. Material transfer agreements (MTAs) represent an important point of departure in such a process. This article explores the need for a uniform MTA in SA and discusses some aspects of the recently gazetted national MTA, which provides a framework that can serve as a safeguard for cross-border transfer of HBMs in the absence of the National Health Act’s chapter 8 regulations in this regard

    Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and In Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model

    Get PDF
    A series of 2,4-disubstituted imidazopyridines, originating from a SoftFocus Kinase library, was identified from a high throughput phenotypic screen against the human malaria parasite Plasmodium falciparum. Hit compounds showed moderate asexual blood stage activity. During lead optimization, several issues were flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, and cardiotoxicity and were addressed through structure–activity and structure–property relationship studies. Pharmacokinetic properties were assessed in mice for compounds showing desirable in vitro activity, a selectivity window over cytotoxicity, and microsomal metabolic stability. Frontrunner compound 37 showed good exposure in mice combined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy in the P. falciparum NOD-scid IL-2Rγnull (NSG) mouse model. Preliminary mechanistic studies suggest inhibition of hemozoin formation as a contributing mode of action

    Benzylated Sulfamethoxazole Derivatives with Improved Safety Profile as Potential Anti-Mycobacterium tuberculosis and Antibacterial Agents

    No full text
    This study focussed on the synthesis of sulfamethoxazole derivatives and their biological evaluation. The sulfamethoxazole derivatives were successfully biologically evaluated against Mycobacterium tuberculosis, Staphylococcus aureus, and Chinese Hamster Ovarian (CHO) cells. The biological evaluation revealed compounds with improved antitubercular activity and antibacterial activity against S. aureus as well as safety profile when compared to the starting material, sulfamethoxazole. The most active compounds against Mycobacterium tuberculosis were3q with 92% inhibition followed by 3s (90%), 3k (88%), 3t (85%), and 3o (84%)
    corecore